

MEDINEX LIMITED
Incorporated in the Republic of Singapore
Registration No. 200900689W

RESPONSE TO QUERIES FROM THE SINGAPORE EXCHANGE SECURITIES TRADING LIMITED (“SGX-ST”) ON THE NOTIFICATION OF CHARGES AGAINST GENERAL PRACTITIONER

The Board of Directors (the "**Board**") of Medinex Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the questions raised by the SGX-ST relating to the Company's announcement dated 20 August 2021 ("**Announcement**") and appends the replies as follows:

Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Announcement.

Question 1 from SGX-ST:

When was Dr. Sen made aware of the investigations by HSA and MOH ("**Investigations**")?

Company's response:-

While Dr. Sen was made aware of investigations being conducted by Health Sciences Authority ("**HSA**") and the Ministry of Health ("**MOH**") in June 2021, there was no official document provided to Dr. Sen during the investigation and Dr. Sen was not aware of the detailed nature of the case until he received the summon letters from the District Judge on 28 July 2021 and the charges by the HSA and the MOH on 19 August 2021.

Question 2 from SGX-ST:

When was the Board made aware of the Investigations? If there was a time lapse between the Board being made aware of the Investigations and the Announcement, please provide reason(s) why there was such time lapse.

Company's response:-

The Company's Executive Director was informed by Dr. Sen in the evening of 19 August 2021 on the charge made against him by the HSA and the MOH. The management of the Company informed the rest of the board members on 20 August 2021, and the relevant announcement was made via SGXNet on 20 August 2021.

Question 3 from SGX-ST:

The Company acquired its interest in Sen Med in March 2019. Please detail the due diligence performed by the Company prior to the acquisition.

Company's response:-

The Company had performed its due diligence prior to the acquisition. Financial due diligence was conducted on Sen Med Holdings Pte. Ltd. ("**Sen Med**") and its subsidiaries for the last two (2) financial years ended 31 December 2017 and 31 December 2018. The profitability analysis and financial effects of the acquisition on the Company's key financial ratios were prepared and set out in the board paper to seek the Board's approval for the proposed acquisition.

The Company had also performed legal due diligence including enquiring on the complaints notified by the Singapore Medical Council (“SMC”) to Dr. Sen in respect of an alleged failure to carry out proper medical checks on foreign workers during a medical screening for two (2) patients in 2012. In April 2019, the SMC considered Dr. Sen’s representations and consented to the withdrawal of the charges.

Question 4 from SGX-ST:

While we note that Dr. Sen is currently able to continue with the operation of the clinics under Sen Med, please confirm if there are any conditions imposed by HSA and/or MOH on Dr. Sen and/or his practice, and to provide details of such condition(s) if any.

Company’s response:-

It is confirmed by Dr. Sen that there are no conditions imposed by the HSA and/or MOH on Dr. Sen and/or his practice at the current stage. The Company would provide an update if there are any changes on this matter.

Question 5 from SGX-ST:

While we note that Dr. Sen is not listed as a key executive officer of the Company, he is a key person in the Company's 55% subsidiary. Please provide the Nominating Committee's assessment of Dr. Sen's suitability to continue as the director of the Company's subsidiary, as well as the bases for such assessment. Please also provide confirmation from the Nominating Committee that it will continue to monitor and re-assess as the situation develops.

Company’s response:-

In consideration that (i) the charges against Dr. Sen are on-going and the outcome of such charges are unknown, (ii) there are currently no conditions or suspension imposed by the HSA and/or the MOH on Dr. Sen and/or his practice, and (iii) Dr. Sen is still able to manage the operation of the clinics and provide quality medical services to his patients, the Nominating Committee of the Company (the “Nominating Committee”) is of the current view that Dr. Sen is suitable to continue as the director of the Company's subsidiary.

The Nominating Committee will continue to monitor the situation, and depending on the outcome of the charges, and the severity of the action taken against Dr. Sen (if any), the Nominating Committee will re-assess his suitability to act as director of the Company’s subsidiary.

As mentioned in the Company’s announcement dated 20 August 2021, the Company has the ability to source for replacement qualified general practitioners and the approval from the Ministry of Health for the change in clinic manager can typically be obtained within one (1) business day. Accordingly, the Company does not expect the charge on Dr. Sen to have any material financial impact on the Group nor affect the business operations of the Group.

Question 6 from SGX-ST:

Please provide the Sponsor's assessment of the above.

Sponsor’s response:-

Based on the Nominating Committee’s assessment above, nothing has come to the current attention of the Sponsor which will affect Dr. Sen’s suitability to act as a director of the Company’s subsidiary.

By Order of the Board

Jessie Low Mui Choo
Executive Director and Chief Executive Officer

25 August 2021

This announcement has been prepared by the Company and reviewed by the Company's Sponsor, Novus Corporate Finance Pte. Ltd. (the "**Sponsor**"), in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #18-03B Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.